Skip to main contentSkip to search and navigation

UEF eREPOSITORY

    • English
    • suomi
  • English 
    • English
    • suomi
  • Login
View Item 
  •   Home
  • Artikkelit
  • Terveystieteiden tiedekunta
  • View Item
  •   Home
  • Artikkelit
  • Terveystieteiden tiedekunta
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case-control study

Thumbnail
Files
Article (271.7Kb)
Self archived version
final draft
Date
2018
Author(s)
Tapiainen, V
Taipale, H
Tanskanen, A
Tiihonen, J
Hartikainen, S
Tolppanen, A-M
Unique identifier
10.1111/acps.12909
Metadata
Show full item record
More information
Research Database SoleCris

Self-archived article

Citation
Tapiainen, V. Taipale, H. Tanskanen, A. Tiihonen, J. Hartikainen, S. Tolppanen, A-M. (2018). The risk of Alzheimer's disease associated with benzodiazepines and related drugs: a nested case-control study.  ACTA PSYCHIATRICA SCANDINAVICA, [Epub ahead of print 31 May 2018], 10.1111/acps.12909.
Rights
© John Wiley & Sons A/S
Licensed under
All rights reserved
Abstract

Objective
To assess the association between benzodiazepine and related drug (BZDR) use and risk of Alzheimer's disease (AD) with cumulative consumption and duration of use based models.

Method
A nationwide nested case–control study of all Finnish community‐dwelling persons who received clinically verified AD diagnosis in 2005–2011 (N = 70 719) and their matched controls (N = 282 862). AD diagnosis was based on DSM‐IV and NINCDS‐ADRDA criteria. BZDR purchases were extracted from the Prescription Register since 1995. The association between BZDR use and AD was assessed using conditional logistic regression with 5‐year lag time between exposure and outcome.

Results
Benzodiazepine and related drug use was associated with modestly increased risk of AD (adjusted OR 1.06, 95% CI 1.04–1.08). A dose–response relationship was observed with both cumulative consumption and duration. Adjustment for other psychotropics removed the cumulative dose–response relationship by attenuating the ORs in the highest dose category.

Conclusion
Benzodiazepine and related drug use in general was associated with modestly increased risk of AD. No major differences were observed between different subcategories of BZDRs (i.e. benzodiazepines, Z drugs, short‐/medium‐acting or long‐acting BZDRs). As dose–response relationship abolished after adjustment for other psychotropics, it is possible that the association may partially be due to antidepressants and/or antipsychotics, or concomitant use of these medications.

Subjects
Alzheimer   pharmacoepidemiology   risk factors   dementia   
URI
https://erepo.uef.fi/handle/123456789/6732
Link to the original item
http://dx.doi.org/10.1111/acps.12909
Publisher
Wiley
Collections
  • Terveystieteiden tiedekunta [1324]
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
OpenUEF
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap
Search

Browse

All of the ArchiveResource types & CollectionsBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subjectThis CollectionBy Issue DateAuthorsTitlesSubjectsFacultyDepartmentFull organizationSeriesMain subject

My Account

Login
University of Eastern Finland
OpenAccess
eRepo
erepo@uef.fi
OpenUEF
Service provided by
the University of Eastern Finland Library
Library web pages
Twitter
Facebook
Youtube
Library blog
 sitemap